NCT07730645 Evaluation of Low-thermal Argon Plasma Devitalization for the Treatment of CIN 2 Versus Standard of Active Surveillance
| NCT ID | NCT07730645 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Tuebingen |
| Condition | Cervical Intraepithelial Neoplasia Grade 2 (CIN2) |
| Study Type | INTERVENTIONAL |
| Enrollment | 264 participants |
| Start Date | 2026-09-24 |
| Primary Completion | 2029-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 264 participants in total. It began in 2026-09-24 with a primary completion date of 2029-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aims to show that treatment with LtAPD works better than a sham treatment or simply monitoring the condition closely without active treatment ("active surveillance"), in achieving complete healing of a tissue abnormality on the cervix called CIN 2, after 6 months. This will be confirmed by examining tissue samples under a microscope (histopathological examination).
Eligibility Criteria
Inclusion Criteria: * Female sex * Age 18 - 40 years at the time of signing the informed consent * Histologically confirmed CIN 2 * Full visibility of the entire transformation zone (Type 1 or Type 2) and entire lesion in colposcopy * Ability to understand the nature of the clinical investigation and voluntarily signs the informed consent document prior to any study-related procedures Exclusion Criteria: * Histologically confirmed CIN other than CIN 2, or indication of (micro-) invasive cervical disease * CIN lesions extending to the vaginal vault or suspicion of endocervical disease * Current pregnancy or planned pregnancy within the next 6 months * Presence of severe local inflammation or active infection * Presence of a severe cardiovascular, neurological, psychiatric, endocrine, or hematological disease, immunocompromised condition or malignant tumor of any origin, as judged by the investigator * Participation in an interfering clinical study, as judged by the investigator
Contact & Investigator
Felix Neis, PD Dr.
PRINCIPAL INVESTIGATOR
University Hospital Tuebingen, Department of Women's Health, Tübingen
Frequently Asked Questions
Who can join the NCT07730645 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 40 Years, studying Cervical Intraepithelial Neoplasia Grade 2 (CIN2). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07730645 currently recruiting?
Yes, NCT07730645 is actively recruiting participants. Contact the research team at martin.weiss@med.uni-tuebingen.de for enrollment information.
Where is the NCT07730645 trial being conducted?
This trial is being conducted at Tübingen, Germany.
Who is sponsoring the NCT07730645 clinical trial?
NCT07730645 is sponsored by University Hospital Tuebingen. The principal investigator is Felix Neis, PD Dr. at University Hospital Tuebingen, Department of Women's Health, Tübingen. The trial plans to enroll 264 participants.